Table 6 Change in NLR and benefit from dCRT.

From: Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy

Baseline

Post-treatment

Case

Progression free survival

Overall survival

Median (95% CI)

P value

Median (95% CI)

P value

High (NLR ≥ 5)

High (NLR ≥ 5)

64

6 (5.04–6.96)

<0.001

10 (9.36–10.64)

<0.001

High (NLR ≥ 5)

Low (NLR < 5)

140

10 (8.95–11.05)

 

14 (12.95–15.05)

 

Low (NLR < 5)

Low (NLR < 5)

251

15 (13.56–16.43)

0.720

20 (19.03–20.97)

0.793

Low (NLR < 5)

High (NLR ≥ 5)

62

14 (11.36–18.64)

 

20.5 (16.91–23.09)

 
  1. Abbreviations: CI: confidence interval.